Catalytic MetalloDrugs – New Therapies for Old Problems

Add to your list(s) Download to your calendar using vCal

• Professor James Cowan, Ohio State University
• Friday 30 March 2012, 14:00-15:00
• Pfizer Lecture Theatre, Department of Chemistry.

If you have a question about this talk, please contact Jonathan Goddard.

Catalytic metallodrugs combine a reactive metal center with a recognition motif for a structured nucleic acid or protein therapeutic target, and demonstrate effective and selective cleavage or modification chemistry. Reactivity is highly dependent on factors that include metal reduction potential, coordination unsaturation, overall charge, the ability of the metal complexes to facilitate generation of ROS , and the degree to which these ROS are either metal-coordinated or diffusible. In contrast to nucleic acid targets that undergo backbone scission, enzyme inactivation appears to arise through oxidative damage to amino acid sidechains in the active site. Reactivity stems primarily from metal associated reactive oxygen species. Catalytic metallodrugs embody several unique advantages over traditional drug “inhibitors” – namely, the target is eliminated, multiturnover activity allows a sub-stoichiometric concentration of catalyst relative to target, improved selectivity, and reduced potential for resistance. Application of this strategy to HCV , HIV, bacterial and cardiovascular protein and RNA targets will be discussed, including solution and cellular assays, and studies of animal models.

This talk is part of the Biological Chemistry Research Interest Group series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• Biological Chemistry Research Interest Group
• Department of Chemistry
• Featured lists
• Pfizer Lecture Theatre, Department of Chemistry
• School of Physical Sciences

Note that ex-directory lists are not shown.